2025
Antibacterial activit of tamoxifen derivatives against methicillin-resistant Staphylococcus aureus
Molina Panadero I, Falcón Torres J, Hmadcha A, Princiotto S, Cutarella L, Mori M, Dallavalle S, Christodoulou MS*, Smani Y*
Frontiers in Pharmacology 2025 Apr 30;16:1549288
The evolutionary replacement of restriction-modification by Ssp antiviral systems is associated with the distribution of prophages in the major clonal group of Acinetobacter baumannii
Moreno-Rodríguez A, Rubio A, Garzón A, Smani Y, Pérez-Pulido AJ
mBio 2025 Sep 10;16(9):e0213525
Editorial: Multidrug resistant bacteria: new therapeutic approaches for a challenging problem
Fernández GC, Smani Y, Gómez SA
Frontiers in Pharmacology 2025 Oct 14;16:1712353
ENOblock synergizes with colistin to treat Acinetobacter baumannii infections
Molina Panadero I, Moreno Rodríguez A, Rey Hidalgo A, de la Cruz M, Sánchez P, Tomás Gallardo L, Samernate T, Sencanski M, Glisic S, Genilloud O, Nonejuie P, Pérez-Pulido AJ, Hmadcha A, Smani Y*
EMBO Molecular Medicine 2025 Dec;17(12):3496-3524
2024
Efficacy of tamoxifen metabolites in combination with colistin and tigecycline in experimental murine models of Escherichia coli and Acinetobacter baumannii
Herrera-Espejo S, Vila-Domínguez A, Cebrero-Cangueiro T, Smani Y, Pachón J, Jiménez-Mejías ME, Pachón-Ibáñez ME
Antibiotics (Basel) 2024 Apr 24;13(5):386t
Solving the antibacterial resistance in Europe: The multipronged approach of the COST Action CA21145 EURESTOP
Seguin-Devaux C, Mestrovic T, Arts JJ, Sen Karaman D, Nativi C, Reichmann D, Sahariah P, Smani Y, Rijo P, Mori M; COST Action CA21145 EURESTOP
Drug Resistance Updates 2024 May;74:101069
Antibiotic discovery with artificial intelligence for the treatment of Acinetobacter baumannii infections
Boulaamane Y, Molina Panadero I, Hmadcha A, Atalaya Rey C, Baammi S, El Allali A, Maurady A, Smani Y*
mSystems 2024 Jun 18;9(6):e0032524
Discovery of new antimicrobial thiophene derivatives with activity against drug-resistant Gram negative-bacteria
Molina-Panadero I, Morales-Tenorio M, García-Rubia A, Ginex T, Eskandari K, Martinez A, Gil C, Smani Y*
Frontiers in Pharmacology 2024 Aug 20;15:1412797
Recent progress in terrestrial biota derived antibacterial agents for medical applications
Vladkova TG, Smani Y, Martinov BL, Gospodinova DN
Molecules 2024 Oct 15;29(20):4889
2023
In vitro and In vivo virulence study of Listeria monocytogenes isolated from the Andalusian outbreak in 2019
Domínguez AV, Ledesma MC, Domínguez CI, Cisneros JM, Lepe JA, Smani Y*
Tropical Medical in Infectious Diseases 2023 Jan 12;8(1):58
Role of blaTEM and OmpC in the piperacillin-tazobactam resistance evolution by E. coli in patients with complicated intra-abdominal infection
Gálvez Benítez L, Ortiz de la Rosa JM, Rodríguez Villodres A, Casimero Soriguer C, Molina Panadero I, Alvarez Marín R, Bonnin R, Naas T, Pachón J, Cisneros JM, Lepe Jímenez JA, Smani Y*
Journal of Infection 2023 Sep;87(3):220-229
In vitro and in vivo evaluation of two beta-lactamase inhibitors against carbapenem-resistant Acinetobacter baumannii
Domínguez AV, Panadero IM, Smani Y*
European Journal of Clinical Microbiology & Infectious Diseases 2023 Nov;42(11):1317-1325
2022
Impact of the immune response modification by lysophosphatidylcholine in the efficacy of antibiotic therapy of experimental models of peritoneal sepsis and pneumonia by Pseudomonas aeruginosa: LPC therapeutic effect in combined therapy
Parra-Millán R, Jiménez-Mejías ME, Ayerbe-Algaba R, Domínguez-Herrera J, Díaz C, Pérez Del Palacio J, Pachón J, Smani Y*
Enfermedades Infecciosas y Microbiología Clínica (Engl Ed) 2022 Jan;40(1):14-21
Tissue engineered in-vitro vascular patch fabrication using hybrid 3D printing and electrospinning
Mayoral I, Bevilacqua E, Gómez G, Hmadcha A, González-Loscertales I, Reina E, Sotelo J, Domínguez A, Pérez-Alcántara P, Smani Y*, González-Puertas P, Mendez A, Uribe S, Smani T, Ordoñez A, Valverde I
Materials Today Bio 2022 Apr 14;14:100252
Anthelmintic drugs for repurposing against Gram-negative bacilli infections
Canturri AM, Smani Y*
Current Medicinal Chemistry 2022;30(1):59-71
Drug re-purposing for the treatment of bacterial infections
Tomás M, Smani Y*
Frontiers in Pharmacology 2022 Aug 5; 13:973730
Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test
Rodríguez Villodres A, Gálvez Benítez L, Arroyo MJ, Méndez G, Mancera L, Vila Domínguez, Lepe Jímenez JA, Smani Y*
Emerging Microbes and Infection 2022 Aug 16; 11(1):2034-2044
2021
AOA-2 derivatives as outer membrane protein A inhibitors for treatment of Gram-negative bacilli infections
Ayerbe-Algaba R, Bayó N, Verdú E, Parra-Millán R, Seco J, Teixidó M, Pachón J, Giralt E, Smani Y*
Frontiers in Microbiology 2021 Feb 12;12:634323
Efficacy of lysophosphatidylcholine as direct treatment in combination with colistin against Acinetobacter baumannii in murine severe infections models
Miró-Canturri A, Ayerbe-Algaba R, Jiménez-Mejías ME, Pachón J, Smani Y*
Antibiotics 2021 Feb 17;10(2):194
Repurposing of the tamoxifen metabolites to combat infections by multidrug-resistant Gram-negative bacilli
Miró-Canturri A, Ayerbe-Algaba R, Vila-Domínguez A, Jiménez-Mejías ME, Pachón J, Smani Y*
Antibiotics 2021 Mar 22;10(3):336
Potential tamoxifen repurposing to combat infections by multidrug-resistant Gram-negative bacilli
Miró-Canturri A, Ayerbe-Algaba R, Del Toro R, Mejías ME, Pachón J, Smani Y*
Pharmaceuticals 2021 May 26;14(6):507
Editorial: Antivirulence drugs against bacterial infections
Imperi F, Chen W, Smani Y*
Frontiers in Microbiology 2021 May 25;12:690672
Semirapid detection of piperacillin/tazobactam resistance and extended-spectrum resistance to β-lactams/β-lactamase inhibitors in clinical isolates of Escherichia coli
Rodríguez-Villodres Á, Gutiérrez Linares A, Gálvez-Benitez L, Pachón J, Lepe JA, Smani Y*
Microbiology Spectrum 2021 Oct 31;9(2):e0080121
Repurposing of the tamoxifen metabolites to treat methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecalis infections
Miró-Canturri A, Vila-Domínguez A, Caretero-Ledesma M, Ayerbe-Algaba R, Pachón J, Jiménez-Mejías ME, Smani Y*
Microbiol Spectrum 2021 Oct 31;9(2):e0040321
Impact of the COVID-19 pandemic on survival in the patients with the intra-abdominal infections
Gálvez-Benítez L, Rodríguez-Villodres Á, Álvarez-Marín R, Jiménez-Rodríguez R, Lepe-Jiménez JA, Pachón J, Smani Y*
Frontiers in Medicine 2021 Oct 20;8:687415
2020
Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli
Rodríguez-Villodres Á, Gil-Marqués ML, Álvarez-Marín R, Bonnin RA, Pachón-Ibáñez ME, Aguilar-Guisado M, Naas T, Aznar J, Pachón J, Lepe JA, Smani Y*
Journal of Antimicrobial Chemotherapy 2020 Jan 1;75(1):77-85
Antibacterial activity of colloidal silver against Gram-negative and Gram-positive bacteria
Vila Domínguez A, Ayerbe Algaba R, Miró Canturri A, Rodríguez Villodres Á, Smani Y*
Antibiotics 2020 Jan 19;9(1):36
Repositioning rafoxanide to treat Gram-negative bacilli infections
Miró-Canturri A, Ayerbe-Algaba R, Villodres ÁR, Pachón J, Smani Y*
Journal of Antimicrobial Chemotherapy 2020 Jul 1;75(7):1895-1905
Role of PstS in the pathogenesis of Acinetobacter baumannii under microaerobiosis and normoxia
Gil-Marqués ML, Labrador Herrera G, Miró Canturri A, Pachón J, Smani Y*, Pachón-Ibáñez ME*
Journal of Infectious Diseases 2020 Sep 1;222(7):1204-1212
2019
Drug repurposing for the treatment of bacterial and fungal infections
Miró-Canturri A, Ayerbe-Algaba R, Smani Y*
Frontiers in Microbiology 2019 Jan 28;10:41
Relationship between different resistance mechanisms and virulence in Acinetobacter baumannii
Espinal P, Pantel A, Rolo D, Marti S, López-Rojas R, Smani Y*, Pachón J, Vila J, Lavigne JP
Microbial Drug Resistance 2019 Jun;25(5):752-760
Escherichia coli causing meningitis in an adult: A case report and experimental characterization of its virulence
Ayerbe Algaba R, Álvarez-Marín R, Praena J, Smani Y*
Enfermedades Infecciosas y Microbiologia Clinica (Engl Ed). 2019 Jun-Jul;37(6):418-419
Prevalence and clinical impact of Streptococcus pneumoniae nasopharyngeal carriage in solid organ transplant recipients
Roca-Oporto C, Cebrero-Cangueiro T, Gil-Marqués ML, Labrador-Herrera G, Smani Y*, González-Roncero FM, Marín LM, Pachón J, Pachón-Ibáñez ME, Cordero E
BMC Infectious Diseases 2019 Aug 6;19(1):697
The anthelmintic oxyclozanide restores the activity of colistin against colistin-resistant Gram-negative bacilli
Ayerbe-Algaba R, Gil-Marqués ML, Miró-Canturri A, Parra-Millán R, Pachón-Ibáñez ME, Jiménez-Mejías ME, Pachón J, Smani Y*
International Journal of Antimicrobial Agents 2019 Oct;54(4):507-512
Phylogeny, resistome, and virulome of Escherichia coli causing biliary tract infections
Rodríguez-Villodres Á, Bonnin RA, Ortiz de la Rosa JM, Álvarez-Marín R, Naas T, Aznar J, Pachón J, Lepe JA, Smani Y*
Journal of Clinical Medicine 2019 Dec 2;8(12):2118
2018
Intracellular Trafficking and Persistence of Acinetobacter baumannii Requires Transcription Factor EB
Parra-Millán R, Guerrero-Gómez D, Ayerbe-Algaba R, Pachón-Ibáñez ME, Miranda-Vizuete A, Pachón J, Smani Y*
mSphere. 2018 Mar 28;3(2):e00106-18.
Efficacy of Colistin and Its Combination With Rifampin in Vitro and in Experimental Models of Infection Caused by Carbapenemase-Producing Clinical Isolates of Klebsiella pneumoniae
Pachón-Ibáñez ME, Labrador-Herrera G, Cebrero-Cangueiro T, Díaz C, Smani Y*, Del Palacio JP, Rodríguez-Baño J, Pascual A, Pachón J, Conejo MC.
Frontiers in Microbiology 2018 May 15;9:912.
Effect of Hypoxia on the Pathogenesis of Acinetobacter baumannii and Pseudomonas aeruginosa In Vitro and in Murine Experimental Models of Infection
Gil-Marqués ML, Pachón-Ibáñez ME, Pachón J, Smani Y*.
Infection and Immunity 2018 Sep 21;86(10):e00543-18.
Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae
Ayerbe-Algaba R, Gil-Marqués ML, Jiménez-Mejías ME, Sánchez-Encinales V, Parra-Millán R, Pachón-Ibáñex ME, Pachón J, Smani Y*.
Frontiers in Cellular and Infection Microbiology 2018 Oct 3;8:348.
In vitro Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant Enterobacteriaceae
Cebrero-Cangueiro T, Álvarez-Marín R, Labrador-Herrera G, Smani Y*, Cordero-Matía E, Pachón J, Pachón-Ibáñez ME.
Frontiers in Cellular and Infection Microbiology. 2018 Oct 18;8:363.
Synergistic activity of an OmpA inhibitor and colistin against colistin-resistant Acinetobacter baumannii: mechanistic analysis and in vivo efficacy
Parra-Millán R, Vila-Farrés X, Ayerbe-Algaba R, Varese M, Sánchez-Encinales V, Bayó N, Pachón-Ibáñez ME, Teixidó M, Vila J, Pachón J, Giralt E, Smani Y*.
Antimicrobial Chemotherapy 2018 Dec 1;73(12):3405-3412.
Relationship Between the Quorum Network (Sensing/Quenching) and Clinical Features of Pneumonia and Bacteraemia Caused by A. baumannii
Fernandez-Garcia L, Ambroa A, Blasco L, Bleriot I, López M, Alvarez-Marin R, Fernández-Cuenca F, Martinez-Martinez L, Vila J, Rodríguez-Baño J, Garnacho-Montero J, Cisneros JM, Pascual A, Pachón J, Bou G, Smani Y*, Tomás M.
Frontiers in Microbiolpgy 2018 Dec 17;9:3105.
2017
Overproduction of Outer Membrane Protein A by Acinetobacter baumannii as a Risk Factor for Nosocomial Pneumonia, Bacteremia, and Mortality Rate Increase
Sánchez-Encinales V, Álvarez-Marín R, Pachón-Ibáñez ME, Fernández-Cuenca F, Pascual A, Garnacho-Montero J, Martínez-Martínez L, Vila J, Tomás MM, Cisneros JM, Bou G, Rodríguez-Baño J, Pachón J, Smani Y*
The Journal of Infectious Diseases 2017 Mar 15;215(6):966-974.
Perspectives for clinical use of engineered human host defense antimicrobial peptides
Pachón-Ibáñez ME, Smani Y*, Pachón J, Sánchez-Céspedes.
FEMS Microbiology Reviews 2017 May 1;41(3):323-342.
Comparison of the in vitro activity of ampicillin and moxifloxacin against Listeria monocytogenes at achievable concentrations in the central nervous system
Pupo I, Lepe JA, Smani Y*, Aznar J.
Journal of Medical Microbiology 2017 Jun;66(6):713-720.
Combating virulence of Gram-negative bacilli by OmpA inhibition
Vila-Farrés X, Parra-Millán R, Sánchez-Encinales V, Varese M, Ayerbe-Algaba R, Bayó N, Guardiola S, Pachón-Ibáñez ME, Kotev M, García J, Teixidó M, Vila J, Pachón J, Giralt E, Smani Y*.
Scientific Reports 2017 Oct 31;7(1):14683.
Heteroresistance to Piperacillin-Tazobactam in Clinical Isolates of Escherichia coli Sequence Type 131
Rodríguez-Villodres Á, Ortiz de la Rosa JM, Álvarez-Marín R, Pachón J, Aznar J, Lepe JA, Smani Y*.
Antimicrobial Agents Chemotherapy 2017 Dec 21;62(1):e01923-17.
2016
Draft Genome Sequences of Seven Multidrug-Resistant Acinetobacter baumannii Strains, Isolated from Respiratory Samples in Spain
Labrador-Herrera G, Álvarez R, López-Rojas R, Smani Y*, Cebrero-Cangueiro T, Rueda A, Pérez Florido J, Pachón J, Pachón-Ibáñez ME.
Genome Announcements 2016 Mar 31;4(2):e00083-16.
New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii
Smani Y*, Pachón-Ibáñez ME, Pachón J.
Expert Opinion on Pharmacotherapy 2016 Jun;17(9):1207-14.
Efficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models
Parra Millán R, Jiménez Mejías ME, Sánchez Encinales V, Ayerbe Algaba R, Gutiérrez Valencia A, Pachón Ibáñez ME, Díaz C, Pérez Del Palacio J, López Cortés LF, Pachón J, Smani Y*.
Antimicrobial Agents and Chemotherapy 2016 Jul 22;60(8):4464-70.
Efficacy of ceftaroline versus vancomycin in an experimental foreign-body and systemic infection model caused by biofilm-producing methicillin-resistant Staphylococcus epidermidis
Domínguez-Herrera J, López-Rojas R, Smani Y*, Labrador-Herrera G, Pachón J.
International Journal of Antimicrobial Agents 2016 Dec;48(6):661-665.
Use of adjuvants in the treatment of Acinetobacter baumannii
Pachón-Ibáñez ME, Smani Y*, Pachón J.
Expert Review of Anti-infective Therapy 2016;14(2):153-5.
2015
Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii
Smani Y*, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J.
Antimicrobial Agents Chemotherapy 2015 Jul;59(7):3920-4.
2014
In vitro and intracellular activities of fosfomycin against clinical strains of Listeria monocytogenes
Lepe JA, Torres MJ, Smani Y*, Parra-Millán R, Pachón J, Vazquez-Barba I, Aznar J.
International Journal of Antimicrobial Agents 2014 Feb;43(2):135-9
Role of OmpA in the multidrug resistance phenotype of Acinetobacter baumannii
Smani Y*, Fàbrega A, Roca I, Sánchez-Encinales V, Vila J, Pachón J.
Antimicrobial Agents Chemotherapy 2014;58(3):1806-8.
2013
Loss of the OprD homologue protein in Acinetobacter baumannii: impact on carbapenem susceptibility
Smani Y*, Pachón J.
Antimicrobial Agents Chemotherapy 2013 Jan;57(1):677.
Treating multidrug-resistant Acinetobacter baumannii infection by blocking its virulence factors
López-Rojas R, Smani Y*, Pachón J.
Expert Review of Anti-infective Therapy 2013 Mar;11(3):231-3.
Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii
Smani Y*, Dominguez-Herrera J, Pachón J.
The Journal of Infectious Diseases 2013 Nov 15;208(10):1561-70.
2012
In vitro and in vivo reduced fitness and virulence in ciprofloxacin-resistant Acinetobacter baumannii
Smani Y*, López-Rojas R, Domínguez-Herrera J, Docobo-Pérez F, Martí S, Vila J, Pachón J.
Clinical Microbiology and Infection 2012 Jan;18(1):E1-4.
Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli
Docobo-Pérez F, Nordmann P, Domínguez-Herrera J, López-Rojas R, Smani Y*, Poirel L, Pachón J.
International Journal of Antimicrobial Agents 2012 Mar;39(3):251-4.
Role of fibronectin in the adhesion of Acinetobacter baumannii to host cells
Smani Y*, McConnell MJ, Pachón J.
PLoS One 2012;7(4):e33073
Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells
Smani Y*, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Ibáñez-Martínez J, Pachón J.
Journal of Biological Chemistry 2012 Aug 3;287(32):26901-10.
2011
Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii
McConnell MJ, Domínguez-Herrera J, Smani Y*, López-Rojas R, Docobo-Pérez F, Pachón J.
Infection and Immunity Journal 2011 Jan;79(1):518-26.
Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii
López-Rojas R, Domínguez-Herrera J, McConnell MJ, Docobo-Peréz F, Smani Y*, Fernández-Reyes M, Rivas L, Pachón J
The Journal of Infectious Diseases 2011 Feb 15;203(4):545-8.
Acinetobacter baumannii-induced lung cell death: role of inflammation, oxidative stress and cytosolic calcium
Smani Y*, Docobo-Pérez F, McConnell MJ, Pachón J.
Microbial Pathogenesis 2011 May;50(5):224-32.
Rifampin protects human lung epithelial cells against cytotoxicity induced by clinical multi and pandrug-resistant Acinetobacter baumannii
Smani Y*, Domínguez-Herrera J, Pachón J.
The Journal of Infectious Diseases 2011 Apr 15;203(8):1110-9
Attenuated virulence of a slow-growing pandrug-resistant Acinetobacter baumannii is associated with decreased expression of genes encoding the porins CarO and OprD-like
Fernández-Cuenca F, Smani Y*, Gómez-Sánchez MC, Docobo-Pérez F, Caballero-Moyano FJ, Domínguez-Herrera J, Pascual A, Pachón J.
International Journal of Antimicrobial Agents 2011 Dec;38(6):548-9.